KR102569055B1 - 아세트알데하이드 독성을 감소시키기 위한 베타-에스신을 포함하는 경구 조성물 - Google Patents

아세트알데하이드 독성을 감소시키기 위한 베타-에스신을 포함하는 경구 조성물 Download PDF

Info

Publication number
KR102569055B1
KR102569055B1 KR1020197014741A KR20197014741A KR102569055B1 KR 102569055 B1 KR102569055 B1 KR 102569055B1 KR 1020197014741 A KR1020197014741 A KR 1020197014741A KR 20197014741 A KR20197014741 A KR 20197014741A KR 102569055 B1 KR102569055 B1 KR 102569055B1
Authority
KR
South Korea
Prior art keywords
alcohol
composition
escine
present
acetaldehyde
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197014741A
Other languages
English (en)
Korean (ko)
Other versions
KR20190087437A (ko
Inventor
카타르지나 코지악
Original Assignee
이에스씨아이랩 에스피. 제트 오. 오.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이에스씨아이랩 에스피. 제트 오. 오. filed Critical 이에스씨아이랩 에스피. 제트 오. 오.
Publication of KR20190087437A publication Critical patent/KR20190087437A/ko
Application granted granted Critical
Publication of KR102569055B1 publication Critical patent/KR102569055B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
KR1020197014741A 2016-11-24 2017-11-24 아세트알데하이드 독성을 감소시키기 위한 베타-에스신을 포함하는 경구 조성물 Active KR102569055B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1619846.7A GB201619846D0 (en) 2016-11-24 2016-11-24 Saponin composition
GB1619846.7 2016-11-24
PCT/IB2017/057395 WO2018096502A1 (en) 2016-11-24 2017-11-24 Oral compositions comprising beta-escin for reducing acetaldehyde toxicity

Publications (2)

Publication Number Publication Date
KR20190087437A KR20190087437A (ko) 2019-07-24
KR102569055B1 true KR102569055B1 (ko) 2023-08-21

Family

ID=58073282

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197014741A Active KR102569055B1 (ko) 2016-11-24 2017-11-24 아세트알데하이드 독성을 감소시키기 위한 베타-에스신을 포함하는 경구 조성물

Country Status (9)

Country Link
US (1) US10799550B2 (https=)
EP (1) EP3544615B1 (https=)
JP (1) JP7070933B2 (https=)
KR (1) KR102569055B1 (https=)
AU (1) AU2017365116B2 (https=)
CA (1) CA3044504A1 (https=)
GB (1) GB201619846D0 (https=)
PL (2) PL430029A1 (https=)
WO (1) WO2018096502A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3860615B1 (en) * 2018-10-05 2024-09-18 Escilab SP. Z O.O. Oral composition comprising b-escin and the use thereof
CN116159145B (zh) * 2023-01-31 2025-04-22 四川大学 含七叶皂苷和/或其盐化合物的转染复合物在促转染的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000344675A (ja) 1999-04-01 2000-12-12 Morishita Jintan Kk アルコール障害予防剤およびそれを含有する食品
WO2007076857A1 (en) 2005-12-30 2007-07-12 Cadbury Holdings Limited Chewing gum composition containing chokeberry

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3533231B2 (ja) * 1993-08-20 2004-05-31 森下仁丹株式会社 アルコール吸収抑制剤
KR101383276B1 (ko) * 2012-03-05 2014-04-08 염장열 아로니아 음료 농축액 및 그 제조방법
KR20140090453A (ko) * 2013-01-09 2014-07-17 (주) 제이비케이자연의학연구소 아로니아 추출물을 함유하는 숙취예방, 숙취해소 또는 간 보호용 조성물
PL405318A1 (pl) * 2013-09-11 2015-03-16 Cezary Bilski Preparat złożony wspomagający odchudzanie na bazie wyciągów roślinnych
KR20160100572A (ko) * 2015-02-16 2016-08-24 학교법인연세대학교 고미가 제거된 남가새 음료 및 이의 제조방법
EP3078381A1 (en) * 2015-04-10 2016-10-12 Warszawski Uniwersytet Medyczny Horse chestnut extract or escins for the treatment of alzheimer's disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000344675A (ja) 1999-04-01 2000-12-12 Morishita Jintan Kk アルコール障害予防剤およびそれを含有する食品
WO2007076857A1 (en) 2005-12-30 2007-07-12 Cadbury Holdings Limited Chewing gum composition containing chokeberry

Also Published As

Publication number Publication date
EP3544615A1 (en) 2019-10-02
JP7070933B2 (ja) 2022-05-18
AU2017365116A1 (en) 2019-05-23
JP2019535779A (ja) 2019-12-12
PL430029A1 (pl) 2021-03-08
US10799550B2 (en) 2020-10-13
GB201619846D0 (en) 2017-01-11
EP3544615B1 (en) 2022-05-18
PL3544615T3 (pl) 2022-09-19
AU2017365116B2 (en) 2023-06-22
US20190321432A1 (en) 2019-10-24
KR20190087437A (ko) 2019-07-24
WO2018096502A1 (en) 2018-05-31
CA3044504A1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
Akinyemi et al. Effect of dietary supplementation of ginger and turmeric rhizomes on angiotensin-1 converting enzyme (ACE) and arginase activities in L-NAME induced hypertensive rats
Viuda‐Martos et al. Pomegranate and its many functional components as related to human health: a review
Akanni et al. In vitro studies to assess the antioxidative, radical scavenging and arginase inhibitory potentials of extracts from Artocarpus altilis, Ficus exasperate and Kigelia africana
Yeh et al. Antihypertensive effects of Hsian-tsao and its active compound in spontaneously hypertensive rats
Dulebohn et al. Effects of blueberry (Vaccinium ashei) on DNA damage, lipid peroxidation, and phase II enzyme activities in rats
KR20180103836A (ko) 포도 및 블루베리 혼합물을 포함하는 특수한 영양용 또는 치료용 제제
KR20140090453A (ko) 아로니아 추출물을 함유하는 숙취예방, 숙취해소 또는 간 보호용 조성물
KR102569055B1 (ko) 아세트알데하이드 독성을 감소시키기 위한 베타-에스신을 포함하는 경구 조성물
JP7655920B2 (ja) 認知障害の治療に使用する組成物
Rtibi et al. Ceratonia siliqua leaves exert a strong ROS-scavenging effect in human neutrophils, inhibit myeloperoxydase in vitro and protect against intestinal fluid and electrolytes secretion in rats
KR101645721B1 (ko) 위장질환 예방 및 치료용 유향 함유 조성물
KR20090112954A (ko) 항동맥경화 활성을 갖는 몰로키아 추출물을 함유하는 식품
WO2009155097A1 (en) Natural product inhibitors of 3dg
Kumar et al. Amelioration of diazepam induced memory impairment by fruit of Cucumis sativus L in aged mice by using animal models of Alzheimer’s disease
KR20190061636A (ko) 검은콩 품종 소청자와 소청 2호 추출물을 이용한 항산화용 조성물과 항염증용 조성물
HK40015220A (en) Oral compositions comprising beta-escin and chokeberry juice for reducing acetaldehyde toxicity
HK40015220B (en) Oral compositions comprising beta-escin and chokeberry juice for reducing acetaldehyde toxicity
US12364730B2 (en) Composition comprising oil palm phenolics for use in the treatment and prevention of colon diseases and for promoting and maintaining gut and general health
Chipofya Neuroprotective effects of rooibos against H2O2-induced cytotoxicity in human neuroblastoma SH-SY5Y cells
Akacha et al. Preventive role of cactus (Opuntia ficus-indica) cladodes on methotrexate induced biochemical, hematological and oxidative damage in rat liver
Jameel Fabrication of functional dairy drink using grapefruit peel extract and studying its health effects
Thorley The effect of exercise and nutritional interventions on promoting adaptations to redox signalling
JP7213019B2 (ja) 血中尿酸値低減剤、並びに、キサンチンオキシダーゼ阻害剤
Ferreira et al. Olive Oil and huntington’s disease
Kamati Modulatory role of rooibos on exercise-induced oxidative stress and performance while exploring influences on the human metabolome and effect of genetic variations

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190522

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201119

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220803

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230427

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230707

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230817

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230817

End annual number: 3

Start annual number: 1

PG1601 Publication of registration